modul
immun
system
address
varieti
specif
nonspecif
approach
mani
agent
synthet
natur
origin
stimulatori
suppress
regulatori
activ
grow
evid
drug
biolog
agent
capabl
modul
singl
pathway
target
limit
valu
immunerel
therapi
system
biolog
approach
gain
interest
compar
monoval
approach
limit
benefit
complic
stimul
interest
use
cocktail
immunodrug
restor
immunostasi
botan
chemic
complex
divers
could
therefor
provid
appropri
combin
synergist
moieti
use
drug
discoveri
import
tradit
medicin
natur
product
drug
discoveri
relat
immunodrug
review
immun
respons
requir
time
interplay
multipl
cell
type
within
specif
microenviron
maintain
immun
homeostasi
select
flexibl
necessari
regul
cell
traffic
homeostat
diseas
condit
provid
differenti
distribut
regul
express
cytokin
receptor
consequ
cytokin
respons
develop
phenotyp
therefor
logic
target
therapeut
immun
modul
immunodrug
includ
synthet
organ
biolog
cytokin
antibodi
microbi
botan
natur
product
influenc
immunoregulatori
cascad
bring
specif
stimulatori
suppress
regulatori
effect
immun
suppress
wide
studi
clinic
applic
histor
botan
mainstay
drug
treatment
current
receiv
attent
sourc
synergist
combin
recent
develop
botan
immunodrug
discoveri
review
although
treatment
cancer
use
activ
immunotherapi
limit
success
passiv
immunotherapi
antibodi
cytokin
therapi
bring
new
hope
wide
studi
approach
consist
wholecel
vaccin
dendrit
cellbas
immunotherapi
peptid
vaccin
mani
clinic
studi
demonstr
safeti
necessarili
efficaci
strategi
moreov
emerg
consensu
efficaci
therapi
activ
sever
compon
immun
system
cytokin
therapi
cancer
anoth
attract
approach
howev
balanc
optim
dose
avoid
toxic
reaction
remain
challeng
sever
cytotox
drug
immunomodulatori
effect
rel
low
dose
exert
immunitydepend
cur
effect
anim
model
cancer
combin
therapi
involv
lowdos
anticanc
agent
cytokin
demonstr
benefit
exampl
combin
appropri
regimen
doxorubicin
plu
interleukin
il
tumour
necrosi
factor
tnf
could
cur
produc
lifelong
immunolog
memori
lymphoma
mous
model
mani
research
demonstr
induct
thelper
th
cytokin
use
specif
adjuv
enhanc
antitumour
immun
prevent
reduc
tumour
growth
trend
substanti
possibl
establish
combin
regimen
base
lowdos
anticanc
drug
specif
cytokin
immunolog
adjuv
immunomodul
could
also
benefici
role
prevent
treatment
infecti
diseas
divers
array
synthet
natur
recombin
compound
avail
synthet
immunomodul
levamisol
isoprinosin
pentoxifillin
thalidomid
signific
microbi
immunomodul
bacil
use
year
nonspecif
activ
immun
system
form
cancer
bladder
infecti
diseas
target
cytokin
consid
one
logic
approach
prevent
treatment
infecti
diseas
substanc
granulocyt
colonystimul
factor
gcsf
interferon
variou
chemokin
synthet
cytosin
phosphateguanosin
cpg
oligodeoxynucleotid
glucan
investig
preclin
clinic
studi
interferon
wide
use
treatment
chronic
infect
particularli
hepat
b
c
virus
pegyl
interferon
recent
develop
pharmaceut
prepar
proven
benefici
nonrespons
patient
particularli
cirrhosi
hepat
c
viru
genotyp
cytokin
shown
potenti
augment
immun
respons
variou
infecti
condit
malign
therapeut
effect
cytokin
blocker
also
report
septic
shock
recent
studi
hepat
c
shown
combin
ribavirin
induc
higher
percentag
lymphocyt
activ
alon
approach
current
examin
potenti
boost
host
immun
respons
fight
infect
mani
immun
target
identifi
potenti
central
control
inflamm
target
activ
tcell
subset
consid
one
ration
approach
biolog
monoclon
antibodi
mab
evalu
patient
autoimmun
disord
limit
clinic
benefit
complic
preval
opportunist
infect
andor
malign
observ
hope
reprogram
host
immun
respons
remain
unfulfil
studi
target
relat
leukocyt
infiltr
leukocytefunct
associ
adhesionreceptorcounterreceptor
pair
intercellular
adhes
progress
howev
develop
human
antibodi
longterm
safeti
evalu
yet
establish
cytokin
therapi
attract
treatment
option
howev
optim
treatment
regimen
respect
dosag
interv
particularli
longterm
safeti
need
explor
use
effector
function
th
cell
consid
one
promis
innov
therapeut
strategi
thu
idea
switch
respons
respons
appear
intrigu
approach
studi
variou
anim
model
autoimmun
diseas
clinic
valid
achiev
newer
target
central
innat
adapt
immun
tolllik
receptor
tlr
complement
system
nuclear
activ
studi
combin
approach
treatment
inflammatori
diseas
appear
promis
particular
combin
methotrex
inhibitor
provid
encourag
result
combin
use
vaccin
immunomodul
innov
strategi
vaccin
design
develop
mani
synthet
biolog
natur
immunomodul
evalu
vaccin
adjuv
administr
cytokin
gene
along
dna
vaccin
shown
achiev
select
modul
tcell
respons
moreov
innat
immun
target
tlr
modul
current
research
abil
provid
effect
adjuv
action
glucan
experiment
adjuv
current
clinic
evalu
differ
vaccin
th
lymphocyt
divid
distinct
phenotyp
subset
eg
ifng
tnfa
eg
effector
cell
classif
base
function
capabl
cytokin
profil
cell
drive
cellular
immun
fight
intracellular
organ
elimin
cancer
cell
stimul
delayedtyp
hypersensit
reaction
contrast
cell
drive
humour
immun
upregul
antibodi
product
fight
extracellular
organ
tcell
homeostasi
immunostasi
requir
fine
balanc
respons
agent
could
exhibit
stimulatori
suppress
regulatori
activ
current
much
literatur
support
view
essenti
immunostasi
mani
tcelldirect
therapi
provid
modest
clinic
benefit
although
view
signal
convers
look
rel
simplist
mediat
signal
transduct
interact
linear
wwwdrugdiscoverytodaycom
manner
within
biochem
matrix
consequ
cytokin
multipl
function
modul
would
expect
result
divers
therapeut
function
complex
crosstalk
signal
network
impos
challeng
discoveri
optim
therapeut
intervent
cancer
research
arriv
consensu
reconstitut
function
import
rather
reconstitut
cell
cytokin
efficaci
therapi
one
multipl
respons
immun
system
activ
trend
indic
futur
immunotherapi
involv
cocktail
drug
concurr
andor
simultan
address
vital
compon
immun
matrix
requir
synergist
combin
homeostat
regul
immun
system
histor
botan
facilit
enrich
drug
discoveri
process
propos
explor
sourc
synergist
combin
mani
herbal
prepar
alter
immun
function
display
array
immunomodulatori
effect
variou
vitro
vivo
studi
herbal
medicin
report
modul
cytokin
secret
histamin
releas
immunoglobulin
secret
class
switch
cellular
coreceptor
express
lymphocyt
express
phagocytosi
recent
studi
use
transgen
mous
model
melanoma
show
anticanc
effect
popular
kampo
medicin
mediat
via
enhanc
antigenspecif
antitumour
cytotox
tlymphocyt
respons
botan
produc
divers
rang
natur
product
antimicrobi
immunomodul
potenti
includ
isoflavonoid
indol
phytosterol
polysaccharid
sesquiterpen
alkaloid
glucan
tannin
mani
immunerel
condit
high
unmet
clinic
need
particularli
true
case
new
virus
phenomenon
increas
antibiot
two
major
way
bioprospect
natur
product
investig
first
classic
method
reli
phytochem
factor
serendip
random
screen
approach
second
use
tradit
knowledg
practic
drug
discoveri
engin
also
known
ethnopharmacolog
approach
time
cost
effect
could
lead
better
success
routin
random
screen
tradit
method
exampl
chines
medicin
japanes
kampo
indian
ayurveda
becom
import
bioprospect
tool
ayurveda
give
separ
class
immunomodulatori
botan
name
rasayana
sever
botan
text
studi
immunomodulatori
properti
potenti
provid
new
scaffold
safer
synergist
cocktail
immunodrug
subsequ
section
exampl
provid
import
botan
base
tradit
knowledg
studi
bioprospect
potenti
immunodrug
botan
array
compound
divers
activ
direct
variou
target
immun
matrix
cancer
infect
inflamm
root
glycyrrhiza
glabra
commonli
known
liquoric
use
sinc
ancient
time
indian
chines
egyptian
greek
roman
medicin
promin
ayurveda
rasayana
cytoprotect
demulc
effect
popular
home
remedi
minor
throat
infect
biolog
activ
substanc
liquoric
root
includ
glycyrrhiz
acid
gl
figur
aglycon
ga
phenol
compound
oligosaccharid
polysaccharid
lipid
sterin
recent
gl
ga
shown
exert
hepatoprotect
effect
via
modul
immunemedi
hepatocyt
toxic
explain
administr
result
downregul
inflamm
liver
gl
report
increas
resist
candida
albican
herp
simplex
infect
anim
model
mani
research
suggest
effect
product
ifn
cytokin
might
one
mechan
involv
antiinfect
process
recent
glycyrrhizin
found
activ
inhibit
replic
sever
acut
respiratori
syndrom
sar
associ
viru
studi
ga
found
effect
compar
ribavirin
pyrazofurin
mycophenol
acid
gl
also
report
modulatori
effect
complement
system
report
indic
gl
block
distal
stage
complement
cascad
suggest
might
role
prevent
tissu
injuri
chronic
hepat
also
autoimmun
inflammatori
diseas
mani
research
report
responsemodifi
activ
flavonoid
chalcon
isol
root
extract
modul
famili
apoptot
regulatori
factor
compon
root
suggest
possibl
mechan
report
cytoprotect
activ
activ
includ
antioxid
chemoprevent
antimicrobi
activ
chemic
modif
gl
ga
tri
signific
improv
antiinflammatori
antiallerg
antiulc
activ
observ
observ
indic
immunemodul
biolog
responsemodifi
activ
associ
gl
uncaria
tomentosa
also
known
cat
claw
highland
peruvian
amazon
use
nativ
hundr
year
treat
immunolog
digest
disord
found
two
chemotyp
plant
occur
natur
differ
alkaloid
pattern
root
one
type
contain
pentacycl
oxindol
contain
tetracycl
oxindol
report
antagonist
activ
tetracycl
oxindol
alkaloid
dosedepend
reduc
activ
pentacycl
oxindol
alkaloid
human
endotheli
cell
aqueou
extract
mixtur
oxindol
alkaloid
shown
posit
influenc
product
suggest
immunoregulatori
activ
one
clinic
studi
extract
exhibit
immun
adjuv
activ
pneumococc
vaccin
result
enhanc
lymphocyt
neutrophil
ratio
persist
antibodi
titr
respons
toward
pneumococc
serotyp
vitro
vivo
gene
express
studi
extract
plant
indic
antiinflammatori
activ
mediat
negat
activ
suppress
synthesi
random
clinic
studi
purifi
extract
rich
pentacycl
alkaloid
demonstr
safer
moder
benefit
patient
activ
rheumatoid
arthriti
compar
take
sulfasalazin
hydroxychloroquinin
cytoprotect
observ
extract
devoid
alkaloid
oxindol
alkaloidfre
fraction
modul
apoptosi
tumour
cell
prolifer
dna
repair
process
lead
cytoprotect
chemic
induc
leucopoenia
rat
model
extract
also
shown
promis
antitumour
activ
mediat
via
select
induct
apoptosi
echinacea
plant
member
composita
famili
three
speci
medicin
interest
echinacea
angustifolia
echinacea
purpurea
echinacea
pallida
use
e
purpurea
base
report
immunolog
properti
four
type
constitu
purport
pharmacolog
activ
molecul
phenol
caffeic
acid
deriv
alkylamid
isobutylamid
polysaccharid
glycoprotein
limit
experiment
evid
wwwdrugdiscoverytodaycom
immunostimulatori
activ
exist
caffeic
acid
deriv
alkylamid
contrast
echinacea
polysaccharid
found
directli
activ
nonspecif
immun
cell
type
monocyt
macrophag
natur
killer
nk
cell
character
echinacea
polysaccharid
best
demonstr
vitro
bioassay
activ
yield
reproduc
vivo
pharmacolog
effect
sever
random
trial
report
health
benefit
echinacea
extract
upper
respiratori
tract
infect
withania
somnifera
ws
known
ashwagandha
indian
ginseng
winter
cherri
also
classifi
rasayana
ayurveda
major
biochem
constitu
ws
root
steroid
alkaloid
steroid
lacton
known
withanolid
much
ws
pharmacolog
activ
attribut
withaferin
withanolid
ws
report
immunomodulatori
antitumour
cytoprotect
antioxid
properti
activ
thought
involv
overal
immunoregulatori
properti
ws
sever
preclin
studi
examin
cytoprotect
potenti
ws
one
studi
ws
exhibit
myeloprotect
tumour
model
without
compromis
antitumour
efficaci
cyclophosphamid
azathioprin
prednisolon
anoth
instanc
cytoprotect
experiment
skin
cancer
observ
reduc
level
glutathion
superoxid
dismutas
catalas
glutathion
peroxidas
return
normal
follow
ws
administr
ws
exhibit
modulatori
effect
cytotox
lymphocyt
product
lead
reduc
tumour
growth
withaferin
found
better
doxorubicin
inhibit
growth
breast
colon
cancer
cell
line
recent
studi
suggest
increas
product
induc
nitric
oxid
synthas
one
possibl
mechan
increas
cytotox
effect
macrophag
expos
ws
extract
moreov
withaferin
combin
radiotherapi
increas
respons
radioresist
tumour
ws
treatment
normal
tumourbear
mice
show
posit
influenc
nk
cell
activ
result
enhanc
cell
kill
mani
studi
includ
demonstr
immunomodulatori
potenti
ws
result
increas
haemolyt
titr
inhibit
delay
type
sensit
increas
phagocyt
activ
macrophag
also
observ
anim
receiv
ws
show
immunoprotect
bordetella
pertussi
infect
evid
increas
antibodi
titr
higher
surviv
percentag
recent
studi
polyherb
formul
contain
ws
exhibit
immunomodulatori
activ
lead
modest
clinic
benefit
group
hiv
patient
observ
suggest
ws
could
use
immunolog
adjuv
multipl
therapeut
benefit
cancer
infect
aid
compar
pharmacolog
investig
ws
ginseng
wstreat
group
show
better
anabol
antistress
activ
ginseng
addit
antiinflammatori
activ
ws
also
report
effect
acutephas
reactant
nitric
oxid
synthas
glycosaminoglycan
synthesi
addit
immunoregul
clinic
studi
ws
shown
moder
analges
antiinflammatori
diseasemodifi
activ
arthriti
patient
anoth
ayurved
rasayana
known
immunomodulatori
cytoprotect
activ
tinospora
cordifolia
tc
chemistri
studi
extens
chemic
constitu
broadli
divid
alkaloid
diterpenoid
steroid
flavonoid
lignan
review
appear
quaternari
alkaloid
biotherapeut
diterpen
glucosid
tc
syringin
cordiol
cordiosid
coriofoliosid
found
possess
immunopotenti
activ
triptolid
tripterygium
wilfordii
diterpenoid
triepoxid
rheumatoid
arthriti
leprosi
mistleto
lectin
viscum
album
lectin
cytostat
apoptot
piperin
piper
longum
alkaloid
antitumour
bioavail
enhanc
matrin
sophora
alopecuoid
alkaloid
antivir
sinomenin
sinomenium
acutum
alkaloid
arthriti
rheumatoid
arthriti
artemisinin
artemisia
annua
sesquiterpen
lacton
psoriasi
autoimmun
disord
asp
acanthopanax
senticosu
polysaccharid
antitumour
apocynin
picrorhiza
kurroa
iridoid
glycosid
cytoprotect
antitumor
shatavarin
asparagu
racemosu
triterpenoid
saponin
immunostimul
vaccin
adjuv
kirin
breweri
spong
agela
mauritianu
anticanc
abbrevi
asp
acanthopanax
senticosu
polysaccharid
much
work
conduct
berberin
jatrorrhizin
tinosporasid
columbin
possibl
mechan
immunomodulatori
activ
elucid
activ
macrophag
lead
increas
granulocytemacrophag
colonystimul
factor
gmcsf
lead
leukocytosi
improv
neutrophil
function
tc
also
report
inhibit
classic
complement
pathway
recent
studi
polysaccharid
deriv
tc
result
activ
nk
cell
complement
system
cytokin
coupl
low
nitric
oxid
synthesi
antitumour
activ
tc
evalu
cultur
hela
cell
reveal
effect
extract
compar
better
doxorubicin
treatment
hepatoprotect
activ
tc
carbon
tetrachlorideinduc
liver
damag
also
report
immunoact
lead
botan
sourc
shown
potenti
cytoprotect
antitumour
antiinfect
antiinflammatori
agent
given
tabl
figur
fraction
botan
immunodrug
scope
agent
remain
quit
vast
analysi
current
immunomodul
strategi
indic
monoval
approach
isol
unlik
restor
immunostasi
attain
statu
complet
therapi
box
complement
emerg
system
biolog
approach
holist
monitor
oper
biolog
process
integr
system
like
multipl
immunemodul
strategi
necessari
achiev
clinic
success
owe
complex
interplay
pathway
need
design
drug
involv
safer
cur
synergist
combin
bioprospect
major
role
identifi
combin
botan
immunodrug
discuss
potenti
offer
addit
therapeut
benefit
address
associ
condit
infect
inflamm
cancer
botan
extract
provid
cytoprotect
anticanc
antiinflammatori
antiinfect
activ
addit
immunoregulatori
activ
exampl
crude
extract
tc
immunostimul
anticanc
cytoprotect
activ
cytoprotect
activ
attribut
polysaccharid
immunostimul
activ
attribut
diterpenoid
recent
research
observ
antimicrobi
activ
coupl
immun
modul
bryostatin
isol
marin
organ
bugula
neritina
antineoplast
activ
along
mimick
effect
recombin
human
gmcsf
three
polysaccharid
krestin
lentinan
scihzophyllum
develop
japanes
scientist
mushroom
clinic
use
adjuv
chemotherapi
polysaccharid
develop
multipurpos
medicin
cytostat
antiinflammatori
antithrombot
activ
similarli
polysaccharid
oxygen
triterpenoid
deriv
ganoderma
lucidum
fungu
tradit
chines
medicin
show
broad
spectrum
pharmacolog
function
exampl
underlin
import
bioprospect
newer
synergist
combin
pharmacolog
agent
although
mani
research
studi
synerg
antagon
botan
systemat
scientif
investig
pharmacodynam
kinet
dose
ayurveda
mean
scienc
life
sanskrit
ayur
mean
life
veda
mean
scienc
aim
holist
manag
health
diseas
remain
one
ancient
medic
system
wide
practic
indian
subcontin
sound
philosoph
experienti
experiment
basischarak
samhita
sushrut
samhita
bc
main
ayurved
classic
describ
botan
along
classif
pharmacolog
therapeut
properti
rasayana
therapi
one
eight
branch
ayurveda
gener
mean
nourish
rejuven
drug
multipl
applic
longev
memori
enhanc
immunomodul
adaptogen
mani
research
suppos
neuroendocrin
immun
axi
theori
explain
rasayana
action
golden
triangl
approach
golden
triangl
approach
promot
effect
integr
tradit
wisdom
power
contemporari
scienc
technolog
evid
base
modern
medicin
holist
strategi
reflect
principl
system
biologythi
provid
holist
wholeperson
heal
viewpoint
alongsid
revers
pharmacologybas
platform
drug
discoveri
interact
requir
tradit
knowledg
particularli
great
tradit
exampl
ayurveda
china
import
role
bioprospect
rasayana
select
class
botan
ayurveda
put
capabl
rejuven
promot
longev
health
box
golden
triangl
integr
modern
medicin
tradit
knowledg
robust
use
scienc
technolog
system
biolog
approach
could
open
new
opportun
immunodrug
therapi
figur
short
botan
immunodrug
could
provid
uniqu
opportun
bioprospect
divers
synergist
chemic
moieti
combin
might
act
multipl
target
improv
therapeut
spectrum
tradit
knowledg
practic
bring
experienti
wisdom
provid
safer
cost
effect
platform
newer
scaffold
immunodrug
discoveri
